JP2018534933A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534933A5 JP2018534933A5 JP2018522685A JP2018522685A JP2018534933A5 JP 2018534933 A5 JP2018534933 A5 JP 2018534933A5 JP 2018522685 A JP2018522685 A JP 2018522685A JP 2018522685 A JP2018522685 A JP 2018522685A JP 2018534933 A5 JP2018534933 A5 JP 2018534933A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562249466P | 2015-11-02 | 2015-11-02 | |
| US62/249,466 | 2015-11-02 | ||
| PCT/US2016/059842 WO2017079121A2 (en) | 2015-11-02 | 2016-11-01 | Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018534933A JP2018534933A (ja) | 2018-11-29 |
| JP2018534933A5 true JP2018534933A5 (enExample) | 2019-12-05 |
Family
ID=57286884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522685A Pending JP2018534933A (ja) | 2015-11-02 | 2016-11-01 | 抗ｉｌ１ｒａｐ抗体、ｉｌ１ｒａｐとｃｄ３を結合する二重特異性抗原結合分子、及びその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20170121420A1 (enExample) |
| EP (1) | EP3371220A2 (enExample) |
| JP (1) | JP2018534933A (enExample) |
| KR (1) | KR20180072820A (enExample) |
| CN (1) | CN108431042A (enExample) |
| AR (1) | AR106555A1 (enExample) |
| AU (1) | AU2016350705A1 (enExample) |
| BR (1) | BR112018008908A2 (enExample) |
| CA (1) | CA3003899A1 (enExample) |
| CL (1) | CL2018001175A1 (enExample) |
| CO (1) | CO2018005695A2 (enExample) |
| CR (1) | CR20180250A (enExample) |
| EA (1) | EA201891084A1 (enExample) |
| EC (1) | ECSP18040535A (enExample) |
| IL (1) | IL259082A (enExample) |
| JO (1) | JO3800B1 (enExample) |
| MA (1) | MA43164A (enExample) |
| MX (1) | MX2018005545A (enExample) |
| NI (1) | NI201800057A (enExample) |
| PE (1) | PE20181310A1 (enExample) |
| PH (1) | PH12018500938A1 (enExample) |
| SG (1) | SG11201803675RA (enExample) |
| TW (1) | TW201734045A (enExample) |
| UY (1) | UY36974A (enExample) |
| WO (1) | WO2017079121A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| JP5940093B2 (ja) | 2011-01-19 | 2016-06-29 | カンタージア アクチエボラーグ | 抗ｉｌ−１ｒａｐ抗体及びヒトを処置するためのそれらの使用 |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| CN108348603B (zh) * | 2015-11-03 | 2023-12-29 | Ambrx公司 | 抗cd3叶酸结合物和其用途 |
| AR107582A1 (es) | 2016-02-03 | 2018-05-16 | Amgen Res Munich Gmbh | Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| JOP20190095A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2018231827A1 (en) * | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| US11370842B2 (en) | 2017-08-01 | 2022-06-28 | City Of Hope | Anti-IL1RAP antibodies |
| EP3489259A1 (en) * | 2017-11-23 | 2019-05-29 | Etablissement Français du Sang | Anti-il-1rap-car-t cells and their use |
| SG11202009681YA (en) | 2018-04-03 | 2020-10-29 | Blueprint Medicines Corp | Ret inhibitor for use in treating cancer having a ret alteration |
| BR112020023508A2 (pt) | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
| JP2022532812A (ja) | 2018-08-16 | 2022-07-20 | カンタージア アクチエボラーグ | 抗ｉｌ１ｒａｐ抗体組成物 |
| TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
| MX2021007589A (es) * | 2018-12-21 | 2021-12-10 | 23Andme Inc | Anticuerpos anti il-36 y procedimientos de uso de estos. |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| AU2020279224B2 (en) | 2019-05-21 | 2024-12-05 | Novartis Ag | Trispecific binding molecules against BCMA and uses thereof |
| CA3143211A1 (en) * | 2019-06-26 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | Il1rap binding proteins |
| WO2021243192A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| PE20230389A1 (es) | 2020-05-27 | 2023-03-06 | Janssen Biotech Inc | Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas |
| CR20220666A (es) | 2020-05-29 | 2023-05-05 | Blueprint Medicines Corp | Composiciones farmacéuticas de pralsetinib |
| PE20231575A1 (es) | 2020-09-14 | 2023-10-04 | Ichnos Sciences SA | Anticuerpos que se unen a il1rap y usos de estos |
| EP4288457A2 (en) * | 2021-02-05 | 2023-12-13 | Boehringer Ingelheim International GmbH | Anti-il1rap antibodies |
| WO2022175255A2 (en) | 2021-02-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Trispecific antibody targeting bcma, gprc5d, and cd3 |
| US12054552B2 (en) * | 2022-09-21 | 2024-08-06 | Sanofi Biotechnology | Humanized anti-IL-1R3 antibody and methods of use |
| CN116574189A (zh) * | 2023-01-30 | 2023-08-11 | 北京智仁美博生物科技有限公司 | 针对人il-36r和/或人il-1r3的多种抗体及其用途 |
| US12649790B2 (en) | 2023-07-03 | 2026-06-09 | Medicovestor, Inc. | Proteins that bind SP17 including fully-human anti-SP17 antibodies |
| US12624097B2 (en) | 2023-07-03 | 2026-05-12 | Medicovestor, Inc. | Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins |
| US12673991B2 (en) | 2023-12-26 | 2026-07-07 | Medicovestor, Inc. | Methods of crosslinking IgG |
| US12121587B1 (en) | 2023-12-26 | 2024-10-22 | Medicovestor, Inc. | Dimeric antibodies |
| US12600795B2 (en) | 2023-12-26 | 2026-04-14 | Medicovestor, Inc. | Oligomeric IgG for immunotherapeutics and diagnostics |
| US12258396B1 (en) * | 2024-02-02 | 2025-03-25 | Medicovestor, Inc. | Methods of using immunotherapeutics that bind folate receptor alpha |
| WO2025201513A1 (zh) * | 2024-03-29 | 2025-10-02 | 珠海丹序生物制药有限公司 | 抗il1rap抗体及其用途 |
| TW202608921A (zh) * | 2024-04-02 | 2026-03-01 | 大陸商信達生物製藥（蘇州）有限公司 | 抗ｉｌ１ｒａｐ抗體以及其用途 |
| CN119371547B (zh) * | 2024-12-05 | 2025-11-28 | 深圳市艾伟迪生物科技有限公司 | 一种抗nRNP/Sm抗体或其抗原结合片段及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| ES2243007T3 (es) | 1997-09-16 | 2005-11-16 | Egea Biosciences Llc | Sintesis quimica completa y sintesis de genes de genomas. |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 １가 항체 및 그의 제조 방법 |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| WO2008119565A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| PL2155788T3 (pl) | 2007-04-03 | 2013-02-28 | Amgen Res Munich Gmbh | Swoiste międzygatunkowe bispecyficzne czynniki wiążące |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| WO2009120905A2 (en) | 2008-03-26 | 2009-10-01 | Cellerant Therapeutics, Inc. | Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |
| EP2352763B2 (en) | 2008-10-01 | 2022-09-21 | Amgen Research (Munich) GmbH | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| MX2011003502A (es) | 2008-10-01 | 2011-09-01 | Micromet Ag | Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies. |
| MX2011004550A (es) | 2008-10-31 | 2011-07-20 | Centocor Ortho Biotech Inc | Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos. |
| CN102596992B (zh) | 2009-02-12 | 2015-09-09 | 詹森生物科技公司 | 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途 |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| GB2472856B (en) * | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| JP5940093B2 (ja) * | 2011-01-19 | 2016-06-29 | カンタージア アクチエボラーグ | 抗ｉｌ−１ｒａｐ抗体及びヒトを処置するためのそれらの使用 |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| WO2014093908A2 (en) | 2012-12-14 | 2014-06-19 | Omt, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
| US20150315279A1 (en) | 2012-12-21 | 2015-11-05 | Cellerant Therapeutics, Inc. | Antibodies that bind membrane-bound il1rap |
| GB201403875D0 (en) * | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
-
2016
- 2016-11-01 BR BR112018008908A patent/BR112018008908A2/pt not_active Application Discontinuation
- 2016-11-01 MX MX2018005545A patent/MX2018005545A/es unknown
- 2016-11-01 EP EP16794880.1A patent/EP3371220A2/en not_active Withdrawn
- 2016-11-01 EA EA201891084A patent/EA201891084A1/ru unknown
- 2016-11-01 WO PCT/US2016/059842 patent/WO2017079121A2/en not_active Ceased
- 2016-11-01 PE PE2018000723A patent/PE20181310A1/es unknown
- 2016-11-01 AU AU2016350705A patent/AU2016350705A1/en not_active Abandoned
- 2016-11-01 US US15/340,149 patent/US20170121420A1/en not_active Abandoned
- 2016-11-01 CR CR20180250A patent/CR20180250A/es unknown
- 2016-11-01 CN CN201680077315.3A patent/CN108431042A/zh active Pending
- 2016-11-01 KR KR1020187015367A patent/KR20180072820A/ko not_active Withdrawn
- 2016-11-01 JP JP2018522685A patent/JP2018534933A/ja active Pending
- 2016-11-01 CA CA3003899A patent/CA3003899A1/en not_active Abandoned
- 2016-11-01 SG SG11201803675RA patent/SG11201803675RA/en unknown
- 2016-11-01 MA MA043164A patent/MA43164A/fr unknown
- 2016-11-02 JO JOP/2016/0235A patent/JO3800B1/ar active
- 2016-11-02 TW TW105135526A patent/TW201734045A/zh unknown
- 2016-11-02 AR ARP160103340A patent/AR106555A1/es unknown
- 2016-11-03 UY UY0001036974A patent/UY36974A/es unknown
-
2018
- 2018-05-01 IL IL259082A patent/IL259082A/en unknown
- 2018-05-02 NI NI201800057A patent/NI201800057A/es unknown
- 2018-05-02 PH PH12018500938A patent/PH12018500938A1/en unknown
- 2018-05-02 CL CL2018001175A patent/CL2018001175A1/es unknown
- 2018-05-29 EC ECIEPI201840535A patent/ECSP18040535A/es unknown
- 2018-05-30 CO CONC2018/0005695A patent/CO2018005695A2/es unknown
-
2019
- 2019-03-20 US US16/358,894 patent/US20190270826A1/en not_active Abandoned